Skip to main content
SpringerLink
Log in

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Introduction: The poor prognosis of non small cell lung cancer (NSCLC), as well as the significant toxicity from many conventional cytotoxic regimens warrants the investigation of combinations of new active agents for treatment. This is a phase I–II (dose-finding, efficacy, and toxicity) study of docetaxel + gemcitabine in patients with stage IIIB-IV NSCLC without prior systemic therapy. Patients were treated in cohorts of 3 with alternating increasing doses of docetaxel and gemcitabine at each level. Patients: Fifty patients were entered, of which 49 were eligible including 28 males and 21 females; 15 stage IIIB and 34 stage IV; median age 57 yrs (35–74). Results: The Maximum Tolerated Dose (MTD) was docetaxel 60 mg/m2 day 1 and gemcitabine 750 mg/m2 d1 & 8, every 21 days. The overall response rate is 20%. Eight patients are not formally assessable for response due to early discontinuation or loss to follow-up and are considered to have progressive disease. The median time to progression (TTP) is 3.5 months (1–25), with 11 pts with at least 7 months TTP. There were 10 pts (20%) with a partial response (PR); 18 (37%) maintained stable disease; 21 (43%) had progressive disease (PD) or were not assessable. Toxicity: Forty-nine patients are evaluable for assessment for toxicity: Grade (Gr) 3/4 toxicity was documented thus: 14 with neutropenia, 1 with anemia, 1 with nausea, 2 liver function, 2 dyspnea, 2 fatigue, 1 allergy, 1 neurologic. Conclusion: This regimen is well tolerated and results in phase I–II testing in this patient population warrant further consideration of the study of docetaxel + gemcitabine for advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society Cancer Facts and Figures, 2003

  2. Minna JD, Pass H, Glatstein E, Ihde DC: Cancer of the lung. In Vincent T. De Vita Jr. et al. (eds), Cancer: Principles & Practice: of Oncology, 3rd edition, JB. Lippincott Co., Philadelphia, 1989

    Google Scholar 

  3. Gralla RJ, Kris MG: Chemotherapy in non-small cell lung cancer: Results of recent trials. Semin Oncol 15(suppl 4): 2–5, 1988

    CAS  Google Scholar 

  4. Casper ES, Gralla RJ, Kelson DP, Citovic E, Golbey RB: Phase II study of high dose cis-diachlorodiammine-platinum (II) in the treatment of non-small cell lung cancer. Cancer Treat Rep 63: 2107–2109, 1979

    CAS  PubMed  Google Scholar 

  5. De Jager R, Longeval I, Klatersky J: High dose cisplatin with fluid and mannitol induced diuresis in advanced lung cancer: A phase II clinical trial of EORTC lung cancer working party (Belgium). Cancer Treat Rep 64: 1341–1346, 1980

    CAS  PubMed  Google Scholar 

  6. Furnas BE, Williams SD, Einhorn LH, Cobleigh MA: Vindesine, an effective agent in the treatment of non-small cell lung cancer. Cancer Treat Rep 66: 1709–1711, 1982

    CAS  PubMed  Google Scholar 

  7. Luedke SL, Luedke DW, Petruska P, Broun GO, Reed G, Leavitt J: Vindesine (VDS) monochemotherapy for non small cell lung cancer: A report of 45 cases. Cancer Treat Rep 66: 1409–1411, 1982

    CAS  PubMed  Google Scholar 

  8. Gralla RJ, Raphael BG, Golbey RB, Young CW: Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treat Rep 63: 1343–1346, 1979

    CAS  PubMed  Google Scholar 

  9. Gralla RJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME et al: Cisplatin and vindesine in combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 95: 414–420, 1981

    CAS  PubMed  Google Scholar 

  10. Woodcock TM, Blumenreich MS, Richman SP, Kubota TT, Gentile PS, Allegra JC: Combination chemotherapy with cis-diammine-dichloroplatinum and vinblastine in advanced non small cell lung cancer. J Clin Oncol 1: 247–250, 1983

    CAS  PubMed  Google Scholar 

  11. Spain RC: Neoadjuvant mitomycin C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: Problems and progress from the perspective of long term follow-up. Semin Oncol 15(Suppl 4): 6–15, 1988

    CAS  PubMed  Google Scholar 

  12. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NEJM 346: 92–98, 2002

    CAS  PubMed  Google Scholar 

  13. Dorr RT, Von Hoff DD: Cancer chemotherapy Handbook, 2nd edition. Appleton & Lange, Norwalk CT, 1994, pp. 259–267

    Google Scholar 

  14. Bruno R, Sanderink GJ: Pharmacokinetics and metabolism of docetaxel (Taxotere). Cancer Surveys: Pharmacokinet Cancer Chemother 17: 305–313, 1993

    CAS  Google Scholar 

  15. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288–291, 1991

    CAS  PubMed  Google Scholar 

  16. Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NCS 628503), a taxol analogue. Cancer Res 51: 4845–4852, 1991

    CAS  PubMed  Google Scholar 

  17. Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol®) and docetaxel (Taxotere®): Not simply two of a kind. Annals of Oncology 5: 495–505, 1994

    CAS  PubMed  Google Scholar 

  18. Extra JM, Rousseau F, Bruno R et al: Phase I and pharmacokinetic study of Taxotere (RP 56976, NSC 628503) given as short I.V. infusion, every 21 days. Cancer Res 53: 1037–102, 1993

    CAS  PubMed  Google Scholar 

  19. Riou JF, Petitgenet O, Combeau C et al: Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Pro Am Assoc Can Res 35: 385, 1994

    Google Scholar 

  20. Francis PA, Rigas JR, Kris MG, Pisters MG, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12: 1232–1237, 1994

    CAS  PubMed  Google Scholar 

  21. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12: 1238–1244, 1994

    CAS  PubMed  Google Scholar 

  22. Burris H, Eckhardt J, Fields S, Rodriguez G, Smith L, Thurman A, Peacock N, Juhn J, Hodges S, Bellet R, Bayssas M, LeBail N, Von Hoff D: Phase II trial of taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 12: 335, 1993

    Google Scholar 

  23. Le Chevalier T: Single agent activity of Gemcitabine in advanced non-small cell lung cancer. Sem Oncol 1996; 23(Suppl 10): 36–42

    CAS  Google Scholar 

  24. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  25. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15: 2996–3018, 1997

  26. Socinski MA, Morris DE, Masters GA, Lilenbaum R: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123: 226S–243S, 2003

    PubMed  Google Scholar 

  27. Georgoulias V, Kouroussis C, Androulakis N, Kakolyris S, Dimopoulos M-A, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, Hatzakis K, Kalbakis K, Kotsakis A, Vardakis N, Vlachonicolis J: Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol 17(3): 914–920, 1999

    CAS  PubMed  Google Scholar 

  28. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Veslemes M, Palamidas Ph, Vlachonikolis I: Platinum-based and non-platinum based chemotherapy in advanced non-small cell lung cancer: A randomized multicentre trial. Lancet 357: 1478–1484, 2001

    CAS  PubMed  Google Scholar 

  29. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Econompoulos T, Tsavdaridis D, Papakostas P, Bacoyianis C, Dimopoulos M: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 17: 3578–3585, 2002

    Google Scholar 

  30. Lorusso V, Carpagnano F, Frasci G, Panza N, Di Rienzo G, Cisternino ML, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S, De Lena M: Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18: 405–411, 2000

    CAS  PubMed  Google Scholar 

  31. Lilenbaum R, Cano R, Schwartz M, Siegel L, Lutzky J, Lewis M, Krill E, Barreras L, Davila E: Gemcitabine and vinorelbine in advanced Nonsmall cell lung carcinoma. Cancer 88: 557–562, 2000

    CAS  PubMed  Google Scholar 

  32. Bajetta E, Chiaria Stani S, De Candis D, Bidoli P, Mariani L, Zilembo N, Pozzi P, Procopio G: Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma: A phase II trial. Cancer 89: 763–768, 2000

    CAS  PubMed  Google Scholar 

  33. Gridelli C, Frontini L, Peronne F, Gallo C, Gulisano M, Cigolari S, Castiblione F, Robbiat SF, Gasparini G, Ianniello GP, Farris A, Locatelli MC, Felletti R, Piazza E: Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses. Br J Cancer 83: 707–714, 2000

    CAS  PubMed  Google Scholar 

  34. Beretta GD, Michetti D, Belometti MO et al: Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 83: 573–576, 2000

    CAS  PubMed  Google Scholar 

  35. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena M: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 2529–2536, 2000

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Southern California—Kenneth Norris Jr. Comprehensive Cancer Center, USA

    Valerie Israel, Scott T. Tagawa, Terry Snyder, Susan Jeffers & Derek Raghavan

  2. California Cancer Medical Center, Los Angeles, CA, 90033

    Valerie Israel

Authors
  1. Valerie Israel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott T. Tagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Terry Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan Jeffers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Derek Raghavan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Israel, V., Tagawa, S.T., Snyder, T. et al. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC). Invest New Drugs 22, 291–297 (2004). https://doi.org/10.1023/B:DRUG.0000026255.34988.96

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000026255.34988.96

Search

Navigation